未知生产厂商
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
MYO-029 is used to treat muscular dystrophy. It binds to and inhibit the activity of myostatin (growth and differentiation factor 8 or GDF-8), a protein that prevents skeletal muscle formation. Muscular dystrophy is characterized by a progressive wasting and weakening of muscle fibers. The disorder can be classified into six major types, all of which are inherited. The common feature of these disorders is absence of one of several proteins involved in linking F-actin (a muscle fiber component) to the sheath of tissue surrounding the fiber.
Investigated for use/treatment in muscular dystrophy.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
